COMPANGY NEWS
25
2025-12
CanWell Pharma Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, CA – CanWell Pharma is pleased to announce its participation in the 44th Annual J.P. Morgan Healthcare Conference (JPM 2026), taking place from January 12–15, 2026, at the Westin St. Francis Hotel in San Francisco. As one of the world’s most prestigious healthcare investment symposium…
22
2025-10
Preliminary Results of CanWell’s CAN1012 (an IFNα-biased TLR7 Agonist) in Combination with Toripalimab was Presented at ESMO 2025
The 2025 European Society for Medical Oncology (ESMO) Annual Congress was held in Oct 17-19, Berlin, Germany. CanWell presented preliminary safety and efficacy data from its Phase 1b/2a clinical trial of CAN1012, a first-in-class IFNα-biased TLR7 agonist, in combination with toripalimab for advanced…
08
2025-08
CanWell will Present Latest ADC Program Updates at 16th World ADC in San Diego, CA (Nov 3-6, 2025)
CanWell Pharma will present its latest development progress at the 16th World ADC held on Nov 3-6, 2025, in San Diego, CA. The presentation will be in the form of a poster. The poster will cover the newest research and development updates on company StarLinker dual/tri-payload ADCs, which had made s…
08
2025-08
CanWell will Present Clinical Updates on an IFN-α Biased TLR7 Agonist CAN1012 at ESMO 2025 – Annual Meeting (October 17-21, 2025)
CanWell Pharma will present latest updates on company clinical development of CAN1012 at ESMO 2025 – Annual Meeting held on October 17-21, 2025 in Berlin. The presentation will be in a poster format during a poster session at the conference. The poster covers newest clinical study updates on t…
08
2025-08
CanWell will attend ADC & Novel Conjugates Partnering & Investment Summit (September 9-10, 2025)
CanWell Pharma will update company’s ADC programs at ADC & Novel Conjugates Partnering & Investment Summit held on September 9-10, 2025 in Boston. It covers newest research updates on StarLinker dual/tri-payload ADCs, which had been making tremendous progress in preclinical efficacy studies …